Art

J-GLOBAL ID：201502216827328300   Reference number：15A1170713

The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial

常染色体優性遺伝性嚢胞腎患者に対するトルバプタンの効果:TEMPO3:4試験からの日本人の患者サブセットのサブグループ分析

Author (9)： MUTO Satoru (Teikyo Univ. School of Medicine, Dep. of Urology, Tokyo, JPN) ,  KAWANO Haruna (Juntendo Univ. Graduate School of Medicine, Dep. of Urology, Hongo 3-1-3, Bunkyo-ku, 113-8431, Tokyo, JPN) ,  HIGASHIHARA Eiji (Kyorin Univ. School of Medicine, Dep. of ADPKD Res., Tokyo, JPN) ,  NARITA Ichiei (Niigata Univ. Graduate School of Medical and Dental Sciences, Div. of Clinical Nephrology and Rheumatology, Niigata, JPN) ,  UBARA Yoshifumi (Toranomon Hospital, Nephrology Center and Okinaka Memorial Inst. for Medical Res., Tokyo, JPN) ,  MATSUZAKI Takayuki (Otsuka Pharmaceutical Co., Ltd., Tokyo, JPN) ,  OUYANG John (Otsuka Pharmaceutical Dev. & Commercialization, Inc., Rockville, MD, USA) ,  TORRES Vicente E. (Mayo Clinic, Div. of Nephrology and Hypertension, Dep. of Internal Medicine, Rochester, MN, USA) ,  HORIE Shigeo (Juntendo Univ. Graduate School of Medicine, Dep. of Urology, Hongo 3-1-3, Bunkyo-ku, 113-8431, Tokyo, JPN)
Material： Clinical and Experimental Nephrology  (Clin Exp Nephrol)
Volume： 19  Issue： 5  Page： 867-877  Publication year： Oct. 2015 
JST Material Number： L3173A  ISSN： 1342-1751  Document type： Article
Article type： 短報  Country of issue： Germany, Federal Republic of (DEU)  Language： ENGLISH (EN)

Thesaurus term： hereditary disease ,...
Semi thesaurus term： *Polycystic kidney, autosomal dominant ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=15A1170713&from=J-GLOBAL&jstjournalNo=L3173A") }}

JST classification (4)： Treatment for congenital diseases,deformities.  (GD03030R) ,  Clinical medicine on digestive system in general  (GH01030P) ,  Drug therapy(=pharmacotherapy)for urogenital diseases  (GM05020V) ,  Clinical application of drugs acting on urinary system  (GW11020C)

Substance index (1)： OPC-41061

Reference (18)：

• Higashihara E, Nutahara K, Kojima N, et al. Prevalence and renal prognosis of diagnosed Autosomal-dominant polycystic kidney disease in Japan. Nephron. 1998;80:421-7.
• Levy M, Feingold J. Estimating prevalence in single-gene kidney diseases progressing to renal failure. Kidney Int. 2000;58:925-43.
• Parikh CR, Dahl NK, Chapman AB, et al. Evaluation of urine biomarkers of kidney injury in polycystic kidney disease. Kidney Int. 2012;81:784-90.
• Grantham JJ, Torres VE, Chapman AB, et al. Volume progression in polycystic kidney disease. N Engl J Med. 2006;354:2122-30.
• Hughes J, Ward CJ, Peral B, et al. The polycystic kidney disease 1 (PKD1) gene encodes a novel protein with multiple cell recognition domains. Nat Genet. 1995;10:151-60.

Terms in the title (7)： 常染色体優性遺伝性嚢胞腎 ,  患者 ,  トルバプタン ,  試験 ,  日本人 ,  サブ ,  グループ分析